Death Toll Surpasses 2,000 as DRC Battles Escalating Ebola Outbreak

The Democratic Republic of Congo is facing one of the most severe health crises in its history as the death toll from the latest Ebola surge has officially climbed past 2,000, approaching the country’s deadliest outbreak on record.

Data released by Congolese health authorities confirms 2,011 fatalities out of 4,381 recorded cases, reflecting a high case fatality rate of nearly 46 percent. First declared in mid-May, the outbreak has rapidly expanded across the conflict-affected eastern and northeastern provinces, beginning in Ituri and reaching into North Kivu.

Health officials warn that the surge has not yet reached its peak. However, Congolese Health Minister Samuel Roger Kamba expressed optimism that containment efforts could bring the spread under control within the next three months.

Severe Obstacles to Response Efforts

The containment campaign faces massive hurdles due to ongoing violence from local armed groups, severe deficiencies in regional healthcare infrastructure, and widespread community mistrust.

Health officials report that standard medical tracking is severely hindered, estimating that healthcare workers are currently identifying only about 30 percent of cases, while roughly 70 percent of victims are dying at home without receiving professional medical care.

Leading virologists and international health experts have voiced concern over the speed and coordination of the national response, noting that organizational friction and delayed interventions have hampered early containment efforts.

### Strain Challenges and Vaccine Trials

The current crisis is driven by the rare Bundibugyo Ebola strain, for which no targeted vaccine currently exists. To combat the spread, World Health Organization (WHO) experts have advised initiating full-scale human trials using the Ervebo vaccine originally developed and approved for the more common Zaire strain to assess whether it offers sufficient cross-protection against Bundibugyo.

The Gavi vaccine alliance is mobilizing doses from its global 500,000-dose stockpile to support the trials in affected zones. Simultaneously, candidate vaccines designed specifically for the Bundibugyo strain are undergoing early-stage clinical evaluations in hopes of providing a long-term solution.